The largest U.S. banks are scrutinizing members of the Federal Reserve for any insight into how the central bank will tinker interest rates.Banksread more
Facebook's cryptocurrency project has already been met with skepticism from policymakers around the world.Technologyread more
The U.S. and China restarted their trade talks, but signs are showing a comprehensive deal could be a long way off, if it happens at all.Marketsread more
Stone, 66, a notorious Republican political operative who has described himself as a "dirty trickster," had previously been dressed down by the judge for his public remarks...Politicsread more
The Biden team's second-quarter Federal Election Commission filing shows that the campaign wrote a check of just over $5,300 on June 28 to Sheehan Associates for "strategic...2020 Electionsread more
See which stocks are posting big moves after the bell on July 16.Market Insiderread more
While the vote served as a show of solidarity for Democrats, it recommended no substantive penalty against Trump.Politicsread more
United Airlines' second-quarter profit tops estimates but questions about the 737 Max linger.Airlinesread more
Three civil rights groups filed a federal lawsuit on Tuesday challenging the Trump administration's new asylum rule, which bars asylum claims from most noncitizens who travel...Politicsread more
Google VP of policy Karan Bhatia started sweating early as hearing chair Ted Cruz brings out an internal presentation created within the company.Technologyread more
At a hearing with the House Judiciary subcommittee on antitrust, an Amazon representative disputed a key argument about how it users sellers' data.Technologyread more
Greenlight Capital's David Einhorn gave up on some investments, but doubled down on one controversial stock, according to a letter sent to his hedge fund's clients Tuesday.
Einhorn said the fund exited a long position in Macy's at a loss after the company reduced financial guidance. He also covered a losing short position in Intuitive Surgical as competition didn't ramp up as expected.
However, the hedge fund manager added to his stake in the chemical firm spun off from DuPont, Chemours.
"We began buying in Q4 2015, believing that TiO2 [titanium dioxide] prices were at or near the bottom. As the market caught up to our thinking, the shares began a rapid recovery, and we held an incomplete position," Einhorn wrote in the letter. "In June, a short recommendation achieved widespread publicity and caused the shares to temporarily retreat, enabling us to complete purchasing our stake at attractive prices."
Einhorn is referencing noted short seller Andrew Left of Citron Research, who posted a negative report on the company in June saying it "is a bankruptcy waiting to happen" as "DuPont dumped these [legal] liabilities into spin-off Chemours. "
When asked to comment by CNBC PRO, the short seller told us: